Check for updates

#### **OPEN ACCESS**

EDITED BY Francesco Chierigo, San Martino Hospital (IRCCS), Italy

REVIEWED BY Ugo Giovanni Falagario, University of Foggia, Italy Gabriele Sorce, University of Montreal Hospital Centre (CRCHUM), Canada Mattia Luca Piccinelli, University of Milan, Italy

\*CORRESPONDENCE Lorenzo Bianchi lorenzo.bianchi3@gmail.com

#### SPECIALTY SECTION

This article was submitted to Genitourinary Oncology, a section of the journal Frontiers in Oncology

RECEIVED 16 September 2022 ACCEPTED 07 October 2022 PUBLISHED 21 October 2022

#### CITATION

Bianchi L, Cercenelli L, Bortolani B, Piazza P, Droghetti M, Boschi S, Gaudiano C, Carpani G, Chessa F, Lodi S, Tartarini L, Bertaccini A, Golfieri R, Marcelli E, Schiavina R and Brunocilla E (2022) 3D renal model for surgical planning of partial nephrectomy: A way to improve surgical outcomes. *Front. Oncol.* 12:1046505. doi: 10.3389/fonc.2022.1046505

#### COPYRIGHT

© 2022 Bianchi, Cercenelli, Bortolani, Piazza, Droghetti, Boschi, Gaudiano, Carpani, Chessa, Lodi, Tartarini, Bertaccini, Golfieri, Marcelli, Schiavina and Brunocilla. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY) The use distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

# 3D renal model for surgical planning of partial nephrectomy: A way to improve surgical outcomes

Lorenzo Bianchi<sup>1,2\*</sup>, Laura Cercenelli<sup>3</sup>, Barbara Bortolani<sup>3</sup>, Pietro Piazza<sup>1</sup>, Matteo Droghetti<sup>1</sup>, Sara Boschi<sup>1</sup>, Caterina Gaudiano<sup>4</sup>, Giulia Carpani<sup>4</sup>, Francesco Chessa<sup>1,2</sup>, Simone Lodi<sup>3</sup>, Lorenzo Tartarini<sup>3</sup>, Alessandro Bertaccini<sup>1,2</sup>, Rita Golfieri<sup>4</sup>, Emanuela Marcelli<sup>3</sup>, Riccardo Schiavina<sup>1,2</sup> and Eugenio Brunocilla<sup>1,2</sup>

<sup>1</sup>Division of Urology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy, <sup>2</sup>Università degli studi di Bologna, Bologna, Italy, <sup>3</sup>eDIMES Lab - Laboratory of Bioengineering, Department of Experimental, Diagnostic and Specialty Medicine (DIMES), University of Bologna, Bologna, Italy, <sup>4</sup>Department of Radiology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy

**Objective:** to evaluate the impact of 3D model for a comprehensive assessment of surgical planning and quality of partial nephrectomy (PN).

**Materials and methods:** 195 patients with cT1-T2 renal mass scheduled for PN were enrolled in two groups: Study Group (n= 100), including patients referred to PN with revision of both 2D computed tomography (CT) imaging and 3D model; Control group (n= 95), including patients referred to PN with revision of 2D CT imaging. Overall, 20 individuals were switched to radical nephrectomy (RN). The primary outcome was the impact of 3D models-based surgical planning on Trifecta achievement (defined as the contemporary absence of positive surgical margin, major complications and  $\leq$ 30% postoperative eGFR reduction). The secondary outcome was the impact of 3D models on surgical planning of PN. Multivariate logistic regressions were used to identify predictors of selective clamping and Trifecta's achievement in patients treated with PN (n=175).

**Results:** Overall, 73 (80.2%) patients in Study group and 53 (63.1%) patients in Control group achieved the Trifecta (p=0.01). The preoperative plan of arterial clamping was recorded as clampless, main artery and selective in 22 (24.2%), 22 (24.2%) and 47 (51.6%) cases in Study group vs. 31 (36.9%), 46 (54.8%) and 7

(8.3%) cases in Control group, respectively (p<0.001). At multivariate logistic regressions, the use of 3D model was found to be independent predictor of both selective or super-selective clamping and Trifecta's achievement.

**Conclusion:** 3D-guided approach to PN increase the adoption of selective clamping and better predict the achievement of Trifecta.

KEYWORDS

3D model, surgical planning, surgical outcomes, renal cancer, partial nephrectomy

## Introduction

Due to the effect of stage migration (1), increasing proportion of patients with renal tumour are diagnosed with T1 stage disease. Thus, partial nephrectomy (PN) is increasingly adopted as preferred treatment (2-4). Recently, the increasing experience with the robotic approach lead to expand the adoption of robotic PN even in complex T1 (5) and T2 renal mass (6-8). Moreover, the risk of unsuccessful PN with conversion to radical nephrectomy (RN) is higher in challenging cases (9, 10). Thus, a critical and detailed comprehension of tumour's complexity is essential to achieve optimal success of PN. Nowadays, 3D models facilitate the understanding of renal anatomy (11, 12) and are more accurate to assess with higher accuracy surgical complexity of renal masses compared to 2D imaging (13, 14) and to predict surgical outcomes (15). Likewise in prostate cancer robotic surgery (16-19), 3D models may have strong implications for surgical planning.

Thus, the high-fidelity 3D reconstruction of renal vasculature allows to increase selective clamping (11–13, 20, 21) with potential improvement of functional outcomes. Thus, oncologic and functional outcomes of PN are dependent on quality of tumour resection, renal ischemia and quality and quantity of preserved renal parenchyma (22). Indeed, ideal outcomes of PN should comprehend maximal renal functional preservation, negative surgical margins and no complications: the simultaneous achievement of all three goals has been defined as Trifecta outcomes (23).

The aim of our study was to evaluate the impact of 3D virtual model for a comprehensive assessment of surgical planning and the improvement of the quality of PN.

# Materials and methods

#### Population

We prospectively enrolled 195 consecutive patients with clinical diagnoses of single T1-T2 renal mass, scheduled for open, laparoscopic or robot assisted PN by experienced surgeons in each surgical technique at the end of the learning curve at our institution between December 2018 and August 2021. Before surgery, each patient was investigated with high quality chest and abdominal contrast-enhanced CT (slice thickness:  $1.25 \div 2.5$  mm, step interval:  $0.8 \div 2.0$  mm). Participants signed a written informed consent document. Patients with multiple synchronous renal tumours and with solitary kidney were excluded.The study was approved by our Institutional Ethics Committee (IRB approval 3386/2018).

To evaluate the impact of 3D virtual model on surgical planning and outcomes of PN, patients were stratified in two groups: Study Group (n= 100), including patients scheduled for PN in which the surgeon reviewed both the 2D CT imaging and the 3D virtual model before and during surgery; Control group (n= 95), including patients scheduled for PN in which the surgeon reviewed only the 2D CT imaging before surgery. Overall, 10 individuals referred to PN were switched to radical nephrectomy (RN) before surgery and 10 patients were switched to RN during surgery, thus the final population of patient underwent PN consisted of 175 patients (91 in Study group and 84 in Control group; Figure 1).

#### 3D modeling

In Study group, all 3D virtual models, based on preoperative high-quality CT scan, were carried out by engineers at eDIMES Lab of the University of Bologna, located at IRCCS, Azienda Ospedaliero-Universitaria, S.Orsola-Malpighi Hospital, as previously described (11, 12).

Briefly, multiple imaging series with different contrast levels were used for the selective identification of each anatomical structure of interest (healthy parenchyma, tumour lesion, extra and intra-renal arterial and venous branches and urinary collecting system [UCS]) in the image segmentation process. Segmentation was achieved using  $D2P^{TM}$  software ('DICOM to PRINT'; 3D Systems Inc., Rock Hill, SC). The segmentation results and the anatomical correctness of the reconstructed 3D virtual models (14, 15) were reviewed and validated by surgeons and radiologists.



For each case in Study group, the surgeon viewed the 3D model before the intervention. Intraoperative viewing of the 3D models was performed at the surgeon's discretion with the help of an assistant. In some cases, the creation of 3D model was not possible due to organisational reasons, since the reconstruction of 3D model required on average about 3 hours by the bioengineers who are involved also in 3D modelling for different surgical specialities. For these cases, patients underwent surgery with 2D imaging only and were included in the Control group.

#### Surgical technique

PNs were performed with open, laparoscopic or robotassisted approach by three dedicated surgeons with high experience in each surgical approach. The choice of surgical technique was left to the surgeon preference. Open PN was performed through a retroperitoneal flank incision between the XI and XII ribs, as previously described (24). Laparoscopic PN and robot-assisted PN were performed with transperitoneal approach as previously described (25, 26). Laparoscopic PN was performed using three 12 mm trocars and one 5 mm trocar. Robot-assisted PN was performed using the DaVinci® Xi<sup>TM</sup> Surgical System (Intuitive Surgical Inc., Sunnyvale, CA, USA) in a four-arm configuration with the integrated Firefly<sup>TM</sup> fluorescence-imaging mode (6). In case of clamping approach to the renal hilum we adopted warm ischemia: a selective (first branch) or super-selective (secondary and tertiary branches) clamping approach was preferred over non selective clamping whenever feasible according to preoperative imaging and intraoperative patients-specific surgical anatomy.

### Surgical planning

The preoperative surgical planning including the need of conversion to RN, the presumed type of arterial clamping technique and the need of UCS suture were evaluated by surgeons on 2D imaging in Control group and both on 2D imaging and 3D virtual models in Study group, consecutively. During surgery, the intraoperative conversion to RN, the effective intraoperative type of clamping and need of UCS suture were recorded and compared to the preoperative planning in both groups.

#### Covariates

Demographic and clinical parameters were available for each patient, including age, body mass index, estimated glomerular filtration rate (eGFR; ml/min/1.73 m<sup>2</sup>) and comorbidities classified according to American Society of Anaesthesiologists (ASA) score. The surgical complexity of the renal masses was scored according to PADUA (27) and R.E.N.A.L (28). score based on 2D imaging in both groups. Prospective data were collected: global surgical time, intraoperative estimated blood loss (EBL), conversion to RN, type of arterial clamping, the need of UCS suture, histotype, pathologic stage and grade and positive surgical margin (PSM). The first postoperative eGFR was considered eGFR at discharge. The variation in eGFR from baseline at discharge was estimated for evaluating the impact of the surgical procedure on renal function. Complications within 30 d after surgery were recorded and graded according to the Clavien-Dindo classification (29). Major complications were categorized as Clavien grade III or higher according to European Association of Urology guidelines (30). During follow up, oncologic outcomes (disease recurrence) evaluated by conventional imaging and functional outcomes were recorded.

#### Outcomes

The primary outcome of the study was to determinate the impact of 3D virtual model to achieve the Trifecta for PN (defined as the contemporary absence of PSM, major complications and  $\leq$ 30% postoperative eGFR reduction) (31).

The secondary outcomes were the impact of 3D models in the preoperative planning of PN with regards of rate of conversion to RN, type of arterial clamping and need of UCS suture and the success rate of the preoperative planning concerning the rate of conversion to RN, type of arterial clamping and need of UCS suture.

#### Statistical analyses

Chi-squared test, T-student test and Mann-Whitney U-test were used to compare proportion, means and medians, respectively. Statistical analyses consist of several steps. First, in the overall population of patients scheduled for PN, the effective rates of conversion to RN planned before surgery or unanticipated and performed during surgery was compared between Study and Control groups. Second, considering patients who effectively underwent PN, the preoperative planning concerning the type of arterial clamping and the need of UCS suture, the effective intraoperative type of arterial clamping and UCS and the success rate of preoperative planning were compared between Study and Control groups. Third, the Trifecta rate and the causes of Trifecta failure were analyzed between the two groups. Finally, multivariate logistic regressions were used to identify independent predictors of selective or super-selective clamping and of Trifecta's achievement, basing on significant predictors at univariate analyses. Covariates consist of follows: age, ASA score, use of 3D models, surgical technique (open, laparoscopic or robotic), PADUA score (Model 1), RENAL score (Model 2). Multivariate logistic regression models to predict conversion to RN and UCS suture were not employed due to limited number of events.

A p value of <0.05 was considered statistically significant. All statistical tests were performed using SPSS 22.0 for Windows.

## Results

Table 1 depicts baseline characteristics in the overall population of patients scheduled for PN (n=195). Surgery was performed with open, laparoscopic or robotic approach in 37 (19%), 25 (12.8%) and 133 (68.2%) cases, respectively. The conversion to RN was planned before surgery in 77.8% and in 27.3% of cases in Study group after revision of the 3D model and in Control group after revision of 2D imaging, respectively (p=0.03). Considering the subgroup of patients referred to PN (n=175), the preoperative plan of arterial clamping was recorded as clampless, main artery, selective or super-selective in 22 (24.2%), 22 (24.2%), and 47 (51.6%) cases in Study group vs. 31 (36.9%), 46 (54.8%) and 7 (8.3%) cases in Control group, respectively (p<0.001). During surgery, the intraoperative management of the renal pedicle was done as preoperatively planned in 63.6% vs. 74.5% of cases for clampless approach

(p=0.05), in 90.1% vs. 76% of cases for main artery clamping (p=0.005) and in 61.7% vs. 28.6% of cases for selective and super-selective clamping (p<0.001) in Study group vs. Control group, respectively. The effective intraoperative need of UCS suture was done as preoperatively planned in 66.6% and 26.1% in Study and Control group, respectively (p=0.004; Table 2). Table 3 shows intra, perioperative, pathologic and postoperative characteristics of individuals who effectively underwent PN (n=175). Overall, 11 and 6 patients in Study group vs. 13 and 4 individuals in Control group experienced Clavien grade I-II and Clavien grade III postoperative complications, respectively (p=0.5). Types of intra- and postoperative complications are reported in Table 4. At mean follow up of 12.5 months, patients underwent PN procedure experienced a mean decrease of eGFR value of -5.8% at discharge. Overall, 80.6% of patients in Study group and 73.4% in Control group had ≤30% postoperative eGFR reduction from baseline at discharge (p=0.01). Overall, 73 (80.2%) and 53 (63.1%) patients achieved the Trifecta for PN in Study and Control group, respectively (p=0.01). Figure 2 depicts the causes of Trifecta's failure in the two groups. At multivariate logistic regressions, the use of 3D model was found to be independent predictor of both adoption of selective or superselective clamping (Odd Radio [OR]:5.26 in model 1 and OR:5.04 in model 2; all  $p \le 0.001$ ) and of Trifecta's achievement (OR:2.42 in model 1 and OR:2.41 in model 2; all  $p \le 0.02$ ; Table 5).

# Discussion

In recent years several technologic improvements have been introduced with the aim to increase the quality of renal surgery. The main goal of PN includes complete tumour excision with negative surgical margins, as well as reduced complications and damage to the healthy renal parenchyma as effect of resection of peritumoral renal tissue or ischemic damage (i.e. Trifecta). Indeed, to reduce the ischemic damage during PN, a nonglobal ischemia techniques have been proposed (32), despite the effect of selective clamping on renal function impairment is still debated. However, the adoption of selective clamping remained less popular in the pre-robotic era due to the need of precise dissection of segmental arterial branches. With the advent of robotics, a more precise surgery that allowed meticulous dissection of higher-order renal arteries was made possible (32). Nevertheless, PN is a complex surgical intervention and an accurate presurgical planning is the key for a good quality of PN outcomes. Before surgery, many aspects should be investigated: planning a conversion to RN, surgical technique, transperitoneal or retroperitoneal approach, selection of blood vessels for clamping, tumor resection margin and need of UCS suture. In the current era of precision surgery, the introduction of 3D models allow to simplify the anatomical knowledge of renal mass and to easily assess the surgical TABLE 1 Patient characteristics and descriptive statistics in the overall population (n=195).

Not of putterns, n(%)     95     100       Age (rears)     67       Mailam (1Q1X)     66 (54-72)     65 (58-70)       Male     64 (69.60)     66 (68)     98       Fermale     28 (30.4)     32 (32)     78       Male     64 (69.60)     65 (88 - 70)     68       Not (Ng/m)     22 (32.2)     2.64 (42-32)     68       SAA core, n (%)     10     71 (71.7)     0.9       3-4     36 (40)     2.63     71 (71.7)     0.9       3-4     38 (40)     2.63     71 (71.7)     0.9       3-4     36 (40)     2.63     71 (71.7)     0.9       3-4     38 (40)     2.63     71 (71.7)     0.9       3-4     38 (40)     2.63     71 (71.7)     0.9       3-4     38 (40)     2.63     71 (71.7)     0.9       Serverstrike tift(g/dl)     14.3 (13-15.3)     14.4 (13-61-54)     67       Molian (102X)     6.8 (0.72-10)     0.68 (0.72-60)     68     67       Serverstrike tift(g/dl)     6.8 (0.7		Control Group (2D imaging)	Study Group (3D model)	P value
Age (ream)(b)(b)Median (QR)(b) (GA72)(b) (GA73)(b)Gondra, n(v)(b) (GA93)(b) (GA93)(b)EM (Gay)(b) (GA93)(b) (GA93)(b) (GA93)(b)EM (GA93)(b) (GA93)(b) (GA93)(b) (GA93)(b) (GA93)(b) (GA93)EA cace, n(v)(b) (GA93)(b)	No. of patients, n (%)	95	100	
Median (10,1%)66 (64-72)65 (58-70)Gander, n.(%)	Age (years)			0.7
Gender, né, né, né, né, né, né, né, né, né, né	Median (IQR)	66 (54-72)	65 (58-70)	
Make64 (62)66 (63)0.8Fende0.8 (0.0)0.8 (0.0)0.8Fende0.8 (0.0)0.8 (0.2 (0.0)0.8ASL scr., (%)7 (7 (7, 7)0.93.40.8 (0.0)0.8 (0.8 (0.0)0.82.40.8 (0.0)0.8 (0.8 (0.0)0.82.40.8 (0.0)0.8 (0.8 (0.0)0.82.50.9 (0.0)0.8 (0.7 (0.0)0.8 (0.7 (0.0)2.60.9 (0.0)0.8 (0.7 (0.0)0.8 (0.7 (0.0)2.60.9 (0.7 (0.0)0.8 (0.7 (0.0)0.8 (0.7 (0.0)2.60.9 (0.7 (0.0)0.8 (0.7 (0.0)0.8 (0.7 (0.0)2.60.9 (0.7 (0.0)0.8 (0.7 (0.0)0.8 (0.7 (0.0)2.60.9 (0.7 (0.0)0.8 (0.7 (0.0)0.8 (0.7 (0.0)2.70.9 (0.1)0.9 (0.1)0.9 (0.1)0.9 (0.1)2.80.9 (0.1)0.9 (0.1)0.9 (0.1)0.9 (0.1)2.90.9 (0.1)0.9 (0.1)0.9 (0.1)0.9 (0.1)2.90.9 (0.1)0.9 (0.1)0.9 (0.1)0.9 (0.1)2.90.9 (0.1)0.9 (0.1)0.9 (0.1)0.9 (0.1)2.90.9 (0.1)0.9 (0.1)0.9 (0.1)0.9 (0.1)2.90.9 (0.1)0.9 (0.1)0.9 (0.1)0.9 (0.1)2.90.9 (0.1)0.9 (0.1)0.9 (0.1)0.9 (0.1)2.90.9 (0.1)0.9 (0.1)0.9 (0.1)0.9 (0.1)2.90.9 (0.1)0.9 (0.1)0.9 (0.1)0.9 (0.1)2.90.9 (0.1)0.9 (0.1)0.9 (0.1)0.9 (0	Gender, n (%)			
Fende28 (30.4)32 (32.9)BMI (QP)22.63 (2.9.2.9)2.64 (2.4.9.5).68AS korer, (N)1.7.1.9.11-23.7 (60)1.7 (17.).0.93-43.63 (0.0)2.62 (3.0.1).7.1Per-opentiv (Lig(Al)1.63 (1.3.1.5.3)1.64 (1.3.6.1.5.4).7.1Per-opentiv Ederitor	Male	64 (69.6)	68 (68)	0.8
Nd Kg/m²)Ads core, m(%)Ads core, m	Female	28 (30.4)	32 (32)	
Median (QR)2.62 (23.9-29)2.64 (24-9.5)0.81ASA scre, n(%)	BMI (Kg/m <sup>2</sup> )			
Askaren (%)1-257 (60)71 (17)0.93-457 (60)28 (23.)1Pre-operative His (xd)14.13-15.3)14.4 (13-15.4)0.7Pre-operative serum Cratific (mgd)0.88 (0.72-10.1)0.88 (0.78-0.98)0.60Pre-operative serum Cratific (mgd)0.88 (0.72-10.1)0.88 (0.78-0.98)0.60Pre-operative serum Cratific (mgd)0.88 (0.72-10.1)0.88 (0.78-0.98)0.60Pre-operative serum Cratific (mgd)0.88 (0.72-10.1)0.88 (0.72-0.10)0.70Median (QR)0.87 (0.74)0.700.700.70CTal0.90 (20.4)2.3 (23.1)0.700.70CTal0.90 (20.4)2.3 (23.1)0.700.70CTal0.90 (20.4)3.6 (27.1)0.700.70CTal0.90 (20.1)0.700.700.70CTal0.90 (10.1)0.900.700.70CTal0.90 (20.1)0.700.700.70CTal0.90 (20.1)0.700.700.70CTal0.90 (20.1)0.700.700.70CTal0.90 (20.1)0.700.700.70CTal0.90 (20.1)0.700.700.70CTal0.90 (20.1)0.700.700.70CTal0.90 (20.1)0.700.700.70CTal0.700.700.700.70CTal0.700.700.700.70CTal0.700.700.700.70CTal0.70	Median (IQR)	26.2 (23.9-29)	26.4 (24-29.5)	0.8
1-257 (60)71 (7.7)0.93-436 (40)28 (28.3)Pre-operative Bill1.43 (13-15.3)1.44 (13-61-54)0.7Median (QR)1.63 (15-15.3)1.84 (13-61-54)0.7Pre-operative serum Centation (mg/dl)0.88 (0.7-0.1)0.88 (0.7-0.1)0.80Pre-operative GRE (ml/main)87 (7-9.8)89 (74-98)0.7Clincal stage, n (%)87 (7-9.8)89 (74-98)0.70.7Clincal stage, n (%)60 (72.6)75 (75)100.3 (23)2.2Clan (CR)3.0 (3.2)2.2 (3)2.110Clan (CR)3.0 (3.2)2.0 (3.1)0.910PADUA sore, n (%)87 (7.9)3.0 (3.1)0.910Intermediate30 (1.1)40 (40)1010PADUA sore, n (%)3.0 (3.1)0.91010Intermediate3.0 (3.1)0.91010Intermediate3.0 (3.1)0.91010Intermediate3.0 (3.1)0.91010Intermediate3.0 (3.1)0.91010Intermediate3.0 (3.1)10.101010Intermediate3.0 (3.1)10.101010Intermediate3.0 (3.1)10.101010Intermediate3.0 (3.1)10.101010Intermediate3.0 (3.1)10.101010Intermediate3.0 (3.1)10.101010Intermediate3.0 (3.1) <td< td=""><td>ASA score, n (%)</td><td></td><td></td><td></td></td<>	ASA score, n (%)			
3438 (a)28 (2s.)Pre-gentive file (juit)Nat (3a (3a (3a (3a (3a (3a (3a (3a (3a (3b	1-2	57 (60)	71 (71.7)	0.9
Pre-operative He (g/d)     14.3 (13-15.3)     14.4 (13-15.4)     0.7       Pre-operative serum Creatinine (mg/d)     0.88 (0.72-10.1)     0.88 (0.78-0.98)     0.6       Pre-operative GER (ml/min)     0.88 (0.72-0.98)     0.7     0.7       Clinical sage, n (%)     0.9 (7.4-98)     89 (74-98)     0.7       Clinical sage, n (%)     0.9 (7.4-98)     89 (74-98)     0.7       Clinical sage, n (%)     0.9 (7.4-98)     2.3 (2.3)     0.7       Clinical sage, n (%)     2.3 (2.3)     2.2 (2.1)     7.7       Clinical sage, n (%)     2.0 (2.1)     0.6     9.7 (7.9)     0.6       PADUA score, n (%)     8.7 (7.10)     3.3 (3.3)     0.9     9.7       Median (IQR)     3.0 (31.6)     3.3 (3.3)     0.9     9.7       Intermediate     3.0 (31.6)     3.6 (3.6)     0.6     9.7     9.7       RINAL score, n (%)     1.0 (0.6)     3.6 (2.6)     0.6     9.7     9.7       RINAL fisk, n (%)     1.0 (1.2)     3.6 (2.6)     0.6     9.7     9.7       Low     3.0 (2.2,1)     1.7 (1.7)	3-4	38 (40)	28 (28.3)	
Net     14.3 (13-15.3)     14.4 (13.61-15.4)     0.7       Pre-operative serum Creatinine (mg/dl)     0.88 (0.73-0.91)     0.88 (0.73-0.93)     0.67       Median (IQR)     0.88 (0.72-0.01)     0.88 (0.73-0.93)     0.7       Pre-operative serum Creatinine (mg/dl)     87 (74-98)     89 (74-98)     0.7       Clinical stage, n (%)     75 (75)     0.9       CTla     69 (72.6)     75 (75)       CTla     0.9 (72.6)     23 (23.2)       CT2a     3 (3.2)     2 (2)       PADUA score, n (%)     85 (7-10)     85 (7-10)       Median (IQR)     8 (7-10)     85 (7-10)     85 (7-10)       PADUA score, n (%)     30 (31.6)     33 (33.3)     0.9       Intermediate     99 (41.1)     40 (40)     14.1       High     26 (27.4)     27 (27.7)     16.6       Rink score, n (%)     71 (6-9)     0.6     16.1       Intermediate     90 (31.4)     34 (30.4)     16.1       Low     33 (34.7)     38 (38)     0.9       Intermediate     50 (52.6)     34 (49.1)     16.1<	Pre-operative Hb (g/dl)			
Pre-operative or Creatinine (mg/dl)     0.88 (0.72-101)     0.88 (0.73-0.98)     0.6       Pre-operative or GRR (m/min)     0.88 (0.72-101)     0.88 (0.73-0.98)     0.7       Median (UQR)     87 (74-98)     89 (74-98)     0.7       Clincal stage, n(%)     0     75 (75)     0.7       CT1a     69 (72.6)     75 (75)     0.7       CT1a     69 (72.6)     23 (23)     212       CT2a     33 (3.2)     2.2 (23)     212       PADUA score, n (%)     8 (7-10)     8 (7-10)     0.6       PADUA score, n (%)     8 (7-10)     8 (7-10)     0.6       PADUA score, n (%)     30 (31.6)     31 (33.0)     0.9       Intermediate     30 (31.6)     31 (33.0)     0.9       High     26 (27.4)     27 (27)     0.6       RNAL sisk, n (%)     100     0.6     0.6       Intermediate     50 (52.6)     49 (49)     0.9       Intermediate     50 (52.6)     49 (49)     0.9       Intermediate     50 (52.6)     49 (49)     0.6       Store of thoRN	Median (IQR)	14.3 (13-15.3)	14.4 (13.6-15-4)	0.7
Number of PR conjective of PR (ml/min)     0.88 (0.72-1.01)     0.88 (0.73-0.98)     0.6       Pre-operative of PR (ml/min)     87 (74-98)     89 (74-98)     0.7       Clinical stage, n (%)     67 (72-6)     75 (75)     0.7       Clinical stage, n (%)     69 (72.6)     75 (75)     0.7       Clinical stage, n (%)     33 (32)     23 (23)     21       Clinical stage, n (%)     33 (32)     2 (2)     23 (23)       PADUA score, n (%)     87 (7-10)     86 (7-10)     86 (7-10)       Median (QR)     30 (31.6)     33 (33)     0.9       PADUA risk, n (%)     33 (33.1)     0.9     10       Intermediate     39 (41.1)     40 (40)     10       High     26 (27.4)     27 (27)     10       RENAL risk, n (%)     10 (10,0)     10 (10,0)     10       Intermediate     10 (21,2)     13 (13)     10       Indefinic (IQR)     32 (22.42)     32 (23.4)     10       Intermediate     10 (21,2)     10 (21,1)     10       Intermediate     10 (21,2)     10     10	Pre-operative serum Creatinine (mg/dl)			
Pre-operative of CRI (ml/min)     87 (74-98)     89 (74-98)     0.7       Clinical stage, n (%)     0.9     0.9       CT la     69 (72.6)     75 (75)       CT la     23 (24.2)     23 (23)       CT2a     3 (32)     2 (2)       PADUA score, n (%)     8 (7-10)     8 (7-10)     0.6       Median (UQR)     80 (31.6)     33 (33)     0.9       Intermediate     39 (41.1)     40 (40)     10       High     26 (27.4)     27 (27)     10       RENAL risk, n (%)     20 (27.4)     27 (27.5)     0.6       RENAL risk, n (%)     7 (6-9)     7 (6-9)     0.6       RENAL risk, n (%)     33 (34.7)     38 (38)     0.9       Intermediate     50 (52.6)     49 (49)     10       Indem (IQR)     3.2 (2.2.4.2)     3 (3.2.4)     0.9       String in discring and the at CT scan (cm)     33 (3.7)     38 (38)     0.9       String in discring in discring and the at CT scan (cm)     10 (21.6)     17 (17)     0.2       String in din discring andig (10.1)     17 (17) <t< td=""><td>Median (IQR)</td><td>0.88 (0.72-1.01)</td><td>0.88 (0.78-0.98)</td><td>0.6</td></t<>	Median (IQR)	0.88 (0.72-1.01)	0.88 (0.78-0.98)	0.6
Mean (QR)     87 (74-98)     99 (74-98)     0.7       Clinical stage, n (%)     09     0.9       cTla     69 (72.6)     75 (75)       cTlb     23 (24.2)     23 (23)       cT2a     3 (32)     2 (2)       PADUA score, n (%)     8 (7-10)     8 (7-10)     0.6       PADUA risk, n (%)     8 (7-10)     8 (7-10)     0.6       PADUA risk, n (%)     30 (31.6)     33 (33)     0.9       Intermediate     39 (41.1)     40 (40)     1       High     26 (27.4)     27 (27)     1       RENAL score, n (%)     7 (6-9)     0.6     6       RENAL risk, n (%)     33 (34.7)     8 (83)     0.9       Intermediate     51 (21.6)     13 (3)     1       Indian (IQR)     3 (2.2.42)     3 (2.2.4)     0.9       Intermediate     52 (2.2.4)     3     0.9       Intermediate functione, mean score, mean s	Pre-operative eGFR (ml/min)			
Clinical stage, n (%)     09       cT la     69 (72.6)     75 (75)       cT lb     23 (24.2)     23 (23)       cT la     3 (32)     23 (23)       cT la     8 (7-10)     8 (7-10)       Median (IQR)     8 (7-10)     8 (7-10)       linermediate     30 (31.6)     33 (33)     0.9       RINAL score, n (%)     7 (6-9)     7 (6-9)     0.6       RENAL risk, n (%)     12 (12.6)     13 (13)     19       Intermediate     50 (52.6)     49 (49)     19       Intermediate condumeter at CT scan (cm)     10     10     10       Surgial technique, n	Median (IQR)	87 (74-98)	89 (74-98)	0.7
CTa     69 (7.6)     75 (75)       CTIb     23 (24.2)     23 (23)       CT2a     3 (3.2)     2 (2)       PADUA score, n (%)     8     7       Median (1QR)     8 (7-10)     0.6       PADUA score, n (%)     0     0.6       PADUA score, n (%)     33 (33)     0.9       Intermediate     39 (41.1)     40 (40)       High     26 (27.4)     27 (27)       RNAL score, n (%)     76 (9)     0.6       RENAL score, n (%)     76 (9)     0.6       RENAL risk, n (%)     1     10 (30)       Intermediate     50 (52.6)     49 (49)       High     12 (12.6)     13 (13)       Intermediate     50 (52.6)     49 (49)       High     12 (12.6)     13 (13)       CInical lesion diameter at CT scan (cm)     1     1       Surgical technique, n (%)     12 (12.6)     19 (9)       Surgical technique, n (%)     9 (9)     0       Conversion to RN n (%)     11 (1.6)     9 (9)       Robotic     59 (62.1)	Clinical stage, n (%)			0.9
CT1b   23 (2.2)   23 (2.2)     CT2a   3 (3.2)   2 (2)     PADUA score, n (%)   8 (7-10)   8 (7-10)   0.6     PADUA risk, n (%)   8 (7-10)   8 (7-10)   0.6     PADUA risk, n (%)   30 (31.6)   33 (33)   0.9     Intermediate   39 (41.1)   40 (40)   10     High   26 (2.4)   27 (27)   7     RENAL score, n (%)   7 (6-9)   7 (6-9)   0.6     RENAL risk, n (%)   7 (6-9)   7 (6-9)   0.6     Intermediate   50 (52.6)   49 (49)   10     High   23 (2.2-4.2)   3 (2.2-4)   0.9     Intermediate at CT scan (cm)   12 (2.6)   13 (3.2)   12     Urigical technique, n (%)   3 (2.1.1)   17 (17)   0.2     Surgical technique, n (%)   10 (10.6)   9 (9)   10     Robotic   59 (62.1)   74 (74)   0.9     Conversion to RN* n (%)   11 (1.6)   9 (9)   0.6     Conversion to RN* n (%)   12 (1.1)   74 (74)   0.9     Robotic   59 (62.1)   74 (74)   0.9 <td>cT1a</td> <td>69 (72.6)</td> <td>75 (75)</td> <td></td>	cT1a	69 (72.6)	75 (75)	
CT2a3 (3.2)2 (2)PADUA score, n (%)8 (7-10)8 (7-10)0.6PADUA risk, n (%)30 (31.6)33 (33)0.9Intermediate39 (41.1)40 (40)10High36 (27.4)27 (2010RENAL score, n (%)7 (6-9)7 (6-9)0.6RENAL risk, n (%)7 (6-9)7 (6-9)0.6Intermediate50 (52.6)49 (49)10High12 (12.6)13 (13.10Character at CT scan (cm)12 (12.6)3 (2.2.4)0.9Surgical technique, n (%)20 (21.1)17 (17)0.2Laproscopic16 (16.8)9 (9)10Conversion to RN* n (%)11 (1.6)9 (9)0.6Conversion to RN* n (%)3 (27.3)7 (77.8)0.3Not planned during surgery8 (72.7)2 (22.2)10	cT1b	23 (24.2)	23 (23)	
PADUA score, n (%)   8 (7-10)   8 (7-10)   0.6     PADUA risk, n (%)   30 (31.6)   33 (33)   0.9     Intermediate   39 (41.1)   40 (40)   10     High   26 (27.4)   27 (27)   10     RENAL score, n (%)   7 (6.9)   7 (6.9)   0.6     Rendia (1QR)   7 (6.9)   7 (6.9)   0.6     Rendia (1QR)   7 (6.9)   0.6   6     Intermediate   33 (34.7)   38 (38)   0.9     Intermediate   50 (52.6)   49 (49)   0.1     Intermediate   12 (12.6)   13 (13)   10     Clinical lesion diameter at CT scan (cm)   12 (2.6)   3 (2.2.4)   0.9     Surgical technique, n (%)   3.2 (2.2.4.2)   3 (2.2.4)   0.9     Clinical lesion diameter at CT scan (cm)   17 (17)   0.2     Surgical technique, n (%)   10 (10.6)   9 (9)   0.6     Chotic   50 (62.1)   47 (4)   0.9   0.6     Conversion to RN n (%)   10.16)   9 (9)   0.6   0.6     Conversion to RN n (%)   10.16)   9 (9)   0.6 <td< td=""><td>cT2a</td><td>3 (3.2)</td><td>2 (2)</td><td></td></td<>	cT2a	3 (3.2)	2 (2)	
Netlan (QR)8 (7-10)8 (7-10)0PADUA risk, n (%) $30 (31.6)$ $33 (33)$ 0.9Intermediate $30 (41.1)$ $40 (40)$ $10 (40)$ High $26 (27.4)$ $27 (27)$ RENAL score, n (%) $7 (6.9)$ $7 (6.9)$ $0.6$ RENAL risk, n (%) $7 (6.9)$ $7 (6.9)$ $0.6$ Renar risk, n (%) $33 (34.7)$ $38 (38)$ $0.9$ Intermediate $50 (52.6)$ $49 (49)$ $10 (12.6)$ $13 (13)$ Clinical lesion diameter at CT scan (cm) $12 (12.6)$ $31 (2.24)$ $0.9$ Surgical technique, n (%) $20 (21.1)$ $17 (17)$ $0.2$ Robotic $59 (62.1)$ $74 (74)$ $0.6$ Conversion to RN n (%) $10 (16.8)$ $9 (9)$ $0.6$ Conversion to RN n (%) $10 (16.8)$ $9 (9)$ $0.6$ Conversion to RN n (%) $10 (16.8)$ $9 (20.1)$ $0.6$ Conversion to RN n (%) $10 (16.8)$ $9 (20.1)$ $0.6$ Conversion to RN n (%) $10 (16.8)$ $9 (20.1)$ $0.6$ Conversion to RN n (%) $10 (16.8)$ $9 (20.1)$ $0.6$ Conversion to RN n (%) $10 (10 (10 (10 (10 (10 (10 (10 (10 (10 ($	PADUA score, n (%)			
PADUA risk, n (%)   30 (31.6)   33 (33)   0.9     Low   30 (31.6)   33 (33)   0.9     Intermediate   39 (41.1)   40 (40)   10     High   26 (27.4)   27 (27)   RENAL score, n (%)   7 (6-9)   0.6     RENAL score, n (%)   7 (6-9)   7 (6-9)   0.6     RENAL risk, n (%)   7   88 (38)   0.9     Intermediate   50 (52.6)   49 (49)   10     High   12 (12.6)   13 (13)   10     Clinical lesion diameter at CT scan (cm)   32 (22-4.2)   3 (2.2-4)   0.9     Surgical technique, n (%)   3.2 (22-4.2)   3 (2.2-4)   0.9     Surgical technique, n (%)   3.2 (2.2-1.2)   3 (2.2-4)   0.9     Surgical technique, n (%)   16 (16.8)   9 (9)   0.2     Laparoscopic   16 (16.8)   9 (9)   0.2     Robotic   59 (62.1)   74 (74)   0.0     Conversion to RN n (%)   10.1   9.0   0.6     Conversion to RN n (%)   3 (27.3)   7 (75.8)   0.03     Not planned (during surgery)   8 (27.2)   2 (	Median (IQR)	8 (7-10)	8 (7-10)	0.6
Low $30 (31.6)$ $33 (33)$ $0.9$ Intermediate $39 (41.1)$ $40 (40)$ High $26 (27.4)$ $27 (27)$ RENAL score, $n (\%)$ $7 (6.9)$ $7 (6.9)$ $0.6$ RENAL risk, $n (\%)$ $7 (6.9)$ $7 (6.9)$ $0.6$ Renal risk, $n (\%)$ $33 (34.7)$ $38 (38)$ $0.9$ Intermediate $50 (52.6)$ $49 (49)$ $10 (10.6)$ High $12 (12.6)$ $13 (13)$ $10 (10.6)$ Clinical lesion diameter at CT scan (cm) $12 (12.6)$ $3 (2.2.4)$ $0.9$ Surgical technique, $n (\%)$ $20 (21.1)$ $17 (17)$ $0.2$ Laparoscopic $16 (16.8)$ $9 (9)$ $10 (10.6)$ $9 (9)$ Robici $59 (62.1)$ $74 (74)$ $10 (10.6)$ Conversion te RN $n (\%)$ $11 (1.6)$ $9 (77.8)$ $0.03 (77.8)$ Not planed (before surgery) $8 (27.2)$ $2 (22.2)$ $10 (12.2)$	PADUA risk, n (%)			
Intermediate     39 (41.)     40 (40)       High     26 (27.4)     27 (27)       RENAL score, n(%)     7 (6-9)     0.6       Median (IQR)     7 (6-9)     0.6       RENAL risk, n(%)     7 (6-9)     0.6       Render     33 (34.7)     38 (38.3)     0.9       Intermediate     50 (52.6)     49 (49)     10       Itarimediate     50 (52.6)     49 (49)     10       Clinical lesion diameter at CT scan (cm)     13 (13)     10     10       Clinical lesion diameter at CT scan (cm)     12 (12.6)     3 (2.2.4)     0.9     0.9       Surgical technique, n (%)     3.2 (2.2.4.2)     3 (2.2.4)     0.9     0.2       Laparoscopic     16 (16.8)     9 (9)     0.2     1.0     0.2       Conversion te RN n (%)     11 (1.6)     9 (9)     0.6     0.6     0.6       Conversion te RN n (%)     11 (1.6)     9 (9)     0.6     0.6     0.6       Conversion te RN n (%)     11 (1.6)     9 (9)     0.6     0.6     0.6     0.6     0.6     0	Low	30 (31.6)	33 (33)	0.9
High   26 (27.4)   27 (27)     RENAL score, n (%)   7 (6-9)   0.6     Median (LQR)   7 (6-9)   0.6     RENAL risk, n (%)   38 (38)   0.9     Low   33 (34.7)   38 (38)   0.9     Intermediate   50 (52.6)   49 (49)   10     High   12 (12.6)   13 (13)   10     Clinical lesion diameter at CT scan (cm)   12 (2.2.4)   3 (2.2.4)   0.9     Surgical technique, n (%)   20 (21.1)   17 (17)   0.2     Laparoscopic   16 (16.8)   9 (9)   0.6     Conversion te Ntn (%)   11 (1.6)   9 (9)   0.6     Conversion te Ntn (%)   11 (1.6)   9 (9)   0.6     Not planned (during surgery)   8 (72.7)   2 (22.2)   10	Intermediate	39 (41.1)	40 (40)	
RENAL score, n (%)   7 (6-9)   7 (6-9)   0.6     Median (IQR)   7 (6-9)   0.6     RENAL risk, n (%)   38 (38)   0.9     Low   33 (34.7)   38 (38)   0.9     Intermediate   50 (52.6)   49 (49)   10     High   12 (12.6)   13 (13)   10     Clinical lesion diameter at CT scan (cm)   32 (2.2-4.2)   3 (2.2-4)   0.9     Surgical technique, n (%)   32 (2.1.1)   17 (17)   0.2     Laparoscopic   16 (16.8)   9 (9)   0     Robotic   59 (62.1)   74 (74)   0     Conversion to RN n (%)   11 (11.6)   9 (9)   0.6     Pre-planned (before surgery)   3 (27.3)   7 (77.8)   0.03	High	26 (27.4)	27 (27)	
Median (UQR)   7 (6-9)   7 (6-9)   0.6     RENAL risk, n (%)   33 (34.7)   38 (38)   0.9     Intermediate   50 (52.6)   49 (49)   0     High   12 (12.6)   13 (13)   1     Clinical lesion diameter at CT scan (cm)   32 (2.2-4.2)   3 (2.2-4)   0.9     Surgical technique, n (%)   32 (2.1.1)   17 (17)   0.2     Qepn   20 (21.1)   17 (17)   0.2     Raparoscopic   59 (62.1)   74 (74)   0.9     Robotic   59 (62.1)   9 (9)   0.6     Conversion to RN n (%)   11 (1.6)   9 (9)   0.6     Pre-planned (before surgery)   3 (27.3)   7 (77.8)   0.03     Not planned (during surgery)   8 (72.7)   2 (22.2)   0.2	RENAL score, n (%)			
RENAL risk, n (%)   33 (34.7)   38 (38)   0.9     Low   33 (34.7)   38 (38)   0.9     Intermediate   50 (52.6)   49 (49)   12 (12.6)   13 (13)     Clinical lesion diameter at CT scan (cm)   12 (12.6)   13 (13)   1     Median (IQR)   3.2 (2.2-4.2)   3 (2.2-4)   0.9     Surgical technique, n (%)   3.2 (2.2-4.2)   3 (2.2-4)   0.9     Surgical technique, n (%)   20 (21.1)   17 (17)   0.2     Laparoscopic   16 (16.8)   9 (9)   0.9     Robotic   59 (62.1)   74 (74)   0.9     Conversion to RN n (%)   11 (11.6)   9 (9)   0.6     Conversion to RN*, n (%)   13 (27.3)   7 (77.8)   0.03     Not planned (during surgery)   8 (72.7)   2 (22.2)   12	Median (IQR)	7 (6-9)	7 (6-9)	0.6
Low     33 (34.7)     38 (38)     0.9       Intermediate     50 (52.6)     49 (49)     1       High     12 (12.6)     13 (13)     1       Clinical lesion diameter at CT scan (cm)     32 (2.2-4.2)     3 (2.2-4)     0.9       Median (IQR)     3.2 (2.2-4.2)     3 (2.2-4)     0.9       Surgical technique, n (%)     20 (21.1)     17 (17)     0.2       Laparoscopic     16 (16.8)     9 (9)     0.2       Robotic     59 (62.1)     74 (74)     0.6       Conversion to RN n (%)     11 (11.6)     9 (9)     0.6       Conversion to RN*, n (%)     3 (27.3)     7 (77.8)     0.03       Not planned (during surgery)     8 (72.7)     2 (22.2)     10	RENAL risk, n (%)			
Intermediate   50 (52.6)   49 (49)     High   12 (12.6)   13 (13)     Clinical lesion diameter at CT scan (cm)   3 (2.2-4.2)   3 (2.2-4)   0.9     Median (IQR)   3.2 (2.2-4.2)   3 (2.2-4)   0.9     Surgical technique, n (%)   17 (17)   0.2     Open   20 (21.1)   17 (17)   0.2     Laparoscopic   16 (16.8)   9 (9)   0     Robotic   59 (62.1)   74 (74)   0.6     Conversion to RN n (%)   11 (11.6)   9 (9)   0.6     Pre-planned (before surgery)   3 (27.3)   7 (77.8)   0.03     Not planned (during surgery)   8 (72.7)   2 (22.2)   0.03	Low	33 (34.7)	38 (38)	0.9
High   12 (12.6)   13 (13)     Clinical lesion diameter at CT scan (cm)   3 (2.2-4.2)   3 (2.2-4)   0.9     Median (IQR)   3.2 (2.2-4.2)   3 (2.2-4)   0.9     Surgical technique, n (%)   17 (17)   0.2     Open   20 (21.1)   17 (17)   0.2     Laparoscopic   16 (16.8)   9 (9)   0.6     Robotic   59 (62.1)   74 (74)   0.6     Conversion to RN n (%)   11 (11.6)   9 (9)   0.6     Pre-planned (before surgery)   3 (27.3)   7 (77.8)   0.03     Not planned (during surgery)   8 (72.7)   2 (22.2)   0.3	Intermediate	50 (52.6)	49 (49)	
Clinical lesion diameter at CT scan (cm)     Median (IQR)   3.2 (2.2-4.2)   3 (2.2-4)   0.9     Surgical technique, n (%)   7   0.2     Open   20 (21.1)   17 (17)   0.2     Laparoscopic   16 (16.8)   9 (9)   0     Robotic   59 (62.1)   74 (74)   0.6     Conversion to RN n (%)   11 (11.6)   9 (9)   0.6     Conversion to RN*, n (%)   7 (77.8)   0.03     Not planned (during surgery)   8 (72.7)   2 (22.2)	High	12 (12.6)	13 (13)	
Median (IQR)     3.2 (2.2-4.2)     3 (2.2-4)     0.9       Surgical technique, n (%)          0.9       Open     20 (21.1)     17 (17)     0.2       2       0.9      0.2       0.9      0.2      0.2      0.2	Clinical lesion diameter at CT scan (cm)			
Surgical technique, n (%)   20 (21.1)   17 (17)   0.2     Depen   20 (21.1)   17 (17)   0.2     Laparoscopic   16 (16.8)   9 (9)   9     Robotic   59 (62.1)   74 (74)   0.6     Conversion to RN n (%)   11 (11.6)   9 (9)   0.6     Conversion to RN*, n (%)	Median (IQR)	3.2 (2.2-4.2)	3 (2.2-4)	0.9
Open   20 (21.1)   17 (17)   0.2     Laparoscopic   16 (16.8)   9 (9)     Robotic   59 (62.1)   74 (74)     Conversion to RN n (%)   11 (11.6)   9 (9)   0.6     Conversion to RN*, n (%)   7 (77.8)   0.03     Not planned (during surgery)   8 (72.7)   2 (22.2)	Surgical technique, n (%)			
Laparoscopic   16 (16.8)   9 (9)     Robotic   59 (62.1)   74 (74)     Conversion to RN n (%)   11 (11.6)   9 (9)   0.6     Conversion to RN*, n (%)   7   77.8)   0.03     Not planned (during surgery)   8 (72.7)   2 (22.2)	Open	20 (21.1)	17 (17)	0.2
Robotic 59 (62.1) 74 (74)   Conversion to RN n (%) 11 (11.6) 9 (9) 0.6   Conversion to RN*, n (%) 9 9 0.6   Pre-planned (before surgery) 3 (27.3) 7 (77.8) 0.03   Not planned (during surgery) 8 (72.7) 2 (22.2)	Laparoscopic	16 (16.8)	9 (9)	
Conversion to RN n (%)     11 (11.6)     9 (9)     0.6       Conversion to RN*, n (%)     7 (77.8)     0.03       Pre-planned (before surgery)     3 (27.3)     7 (77.8)     0.03       Not planned (during surgery)     8 (72.7)     2 (22.2)     2	Robotic	59 (62.1)	74 (74)	
Conversion to RN*, n (%)7 (77.8)0.03Pre-planned (before surgery)3 (27.3)7 (77.8)0.03Not planned (during surgery)8 (72.7)2 (22.2)	Conversion to RN n (%)	11 (11.6)	9 (9)	0.6
Pre-planned (before surgery)     3 (27.3)     7 (77.8)     0.03       Not planned (during surgery)     8 (72.7)     2 (22.2)	Conversion to RN*, n (%)	. /		
Not planned (during surgery) 8 (72.7) 2 (22.2)	Pre-planned (before surgery)	3 (27.3)	7 (77.8)	0.03
	Not planned (during surgery)	8 (72.7)	2 (22.2)	

3D, 3 Dimensional; IQR, Interquartile Range; ASA, American Society of Anesthesiologists; BMI, Body Mass Index; Hb, hemoglobin; eGFR, estimated glomerular filtration rate; CT, computed tomography.

\*Considering patient with conversion to radical nephrectomy.

complexity (14), allowing a patient-tailored approach for PN (15).

Several points of our study are remarkable. First, the use of 3D model allows to significantly reduce the intraoperative

conversions to RN. In our cohort the overall rate of conversion to RN (10.3%) is consistent with previously reported data from very high-volume centres in which it ranges from 3.1% (10) including only robotic cases to 12.4%

	Control Group (2D imaging)	Study Group (3D model)	P value
Preoperative planning of arterial clamping, n (%)			< 0.001
Clampless	31 (36.9)	22 (24.2)	
Main artery	46 (54.8)	22 (24.2)	
Selective (I order branch) or Super selective (II - III order branch)	7 (8.3)	47 (51.6)	
Effective Intraoperative arterial clamping, n (%)			< 0.001
Clampless	31 (36.9)	26 (28.6)	
Main artery	45 (53.6)	32 (35.2)	
Selective (I order branch) or Super selective (II - III order branch)	8 (9.5)	33 (36.3)	
Effective Intraoperative Clamping approach as previously planned, n (%)			
Clampless	23 (74.2)	14 (63.6)	0.05
Main artery	35 (76.1)	20 (90.1)	0.005
Selective (I order branch) or Super selective (II - III order branch)	2 (28.6)	29 (61.7)	< 0.001
Preoperative planning of caliceal suture, n (%)	23 (27.7)	27 (29.7)	0.8
Intraoperative need of caliceal suture, n (%)	7 (8.3)	21 (23.3)	0.007
Effective Intraoperative need of caliceal suture as previously planned, n $(\%)$	6 (26.1)	18 (66.6)	0.004

TABLE 2 Sub-analysis in patients underwent PN (n= 175) to compare the preoperative planning and the intraoperative approach to the renal hilum and caliceal system suturing.

(33) including both open, laparoscopic and robotic approach. Reason for unsuccessful PN may consist of patients-related factors, tumor-related features (9, 34) or surgeons and center experience (3, 33). As consequence, a precise evaluation of complexity of renal mass is the key to achieve successful PN. Our results suggest that the use of 3D model may predict the occurrence of unsuccessful PN, changing the indication from PN to RN before surgery allowing a better patients selection for PN, reducing the intraoperative conversion to RN that may be associated with longer operating times, increased blood loss, and worse postoperative renal function compared to non-converted RN (9, 10) (Figure 3). Second, our data confirmed that the effective intraoperative adoption of selective clamping was significantly higher in patients with 3D model available (36.3%) compared to patients with only 2D imaging (9.5%;

p<0,001). Contrarily to previous reports by Michiels et al. (22) in which most patients with 3D model underwent PN without clamping (50.9%), while the vast majority of patients without 3D model underwent PN with main artery clamping (91.7%), in our cohort the rate of effective clampless approach was significantly higher in control group (36.9%) compared to patients with 3D model (28.6%). This could be due to surgeons' and centres' experience and preference: in our experience we noticed that when 3D model is not available the surgeon is more prone to clamp the main artery in case of complex mass or to perform clampless PN in case of easier cases. Besides, when the 3D model is available, a selective or super-selective clamping is planned and attempt even in easier cases that would have been treated with clampless approach whenever the 3D model was not available, to achieve better bleeding control. To note, the



in patients underwent PN in Control group who did not reach the Trifecta (n=31/84).

	Control Group (2D imaging)	Study Group (3D model)	P value
WIT (min)*			0.9
Median (IQR)	14 (10 -18)	13.5 (10 -20)	
Operative time (min)			0.2
Mean ± SD	$164\pm 64$	$178 \pm 63$	
Resection technique, n (%)			0.08
Standard partial nephrectomy	32 (38.1)	23 (25.6)	
Simple enucleation	52 (61.9)	67 (74.4)	
Time of renal defatting (min)			0.9
Mean ± SD	23 ± 19	23 ± 13	
Time of hilum dissection (min)			0.9
Mean ± SD	19 ± 13	$19 \pm 11$	
Time of enucleation (min)			0.9
Mean ± SD	11 ± 7	12 ± 15	
Estimated blood loss (ml)			0.6
Mean ± SD	$140 \pm 50$	$130 \pm 40$	
Intraoperative complications, n (%)	5 (6)	4 (4.4)	0.6
Post-operative complications grade, n (%)			0.8
Overall	17 (20.2)	17 (18.7)	
-Clavien 1-2	13 (15.5)	11 (12.1)	
-Clavien 3	4 (4.8)	6 (6.6)	
Positive Surgical Margins, n (%)	7 (8.3)	4 (4.4)	0.3
Length of stay (days)			0.6
Median (IQR)	4 (4-5)	4 (3-5)	
Pathological lesion diameter (cm)			0.6
Mean ± SD	3 ± 1.5	$3.4 \pm 1.5$	
Pathology, n (%)			0.8
Benign	18 (21.4)	17 (18.7)	
Clear cell carcinoma	38 (45.2)	47 (51.6)	
Papillary carcinoma	15 (17.9)	13 (14.3)	
Chromophobe carcinoma	9 (10.7)	12 (13.2)	
Other malignancies	4 (4.8)	2 (2.2)	
Pathological stage, n (%)			0.3
pTla	59 (70.2)	65 (71.4)	
pT1b	17 (20.2)	23 (25.3)	
pT2a	1 (2.2)	1 (1.1)	
pT3a	7 (8.3)	2 (2.2)	
Follow up time, months			
Mean ± SD	$15 \pm 12$	$13 \pm 11$	0.06
Postoperative eGFR (ml/min/1.73 $m^2)$ at discharge, Mean $\pm$ SD	73 ± 26	77 ± 21	0.2
Variation in eGFR (ml/min) from baseline at discharge (%)			
Mean ± SD	$-6.2 \pm 20$	$-5.5 \pm 20$	0.2
${\leq}30\%$ postoperative eGFR reduction from baseline at discharge, n (%)	62 (73.4)	79 (80.6)	0.03
Recurrence, n (%)			
Yes	0 (0)	2 (3.1)	0.4
Trifecta achievement, n (%)	53 (63.1)	73 (80.2)	0.01

TABLE 3 Intraoperative, peri-operative, pathologic and postoperative characteristics in the overall population underwent PN (n=175).

\*Considering patient underwent on clamping approach; WIT, Warm Ischemia Time; SD, standard deviation; eGFR, estimated glomerular filtration rate. Trifecta achievement: contemporary absence of positive surgical margins, major complications and ≤30% postoperative eGFR reduction.

	Control Group (2D model)	Study Group (3D imaging)	P value	
INTRAOPERATIVE COMPLICA	TIONS			
Bleeding, n (%)	4 (4.2)	3 (3)	0.7	
Pleuric lesion, n (%)	1 (1.1)	1 (1)	0.9	
POSTOPERATIVE COMPLICAT	TIONS (<30 days)			
TVP-TEP, n (%)	0 (0)	1 (1)	0.3	
Cardiac, n (%)	4 (4.2)	4 (4)	0.9	
Ileus, n (%)	0 (0)	1 (1)	0.3	
Infection, n (%)	7 (7.4)	5 (5)	0.5	
AKI, n (%)	4 (95)	5 (5)	0.8	
Bleeding, n (%)	6 (6.3)	5 (5)	0.7	
Pleural effusion, n (%)	1 (1.1)	0 (0)	0.3	
Pneumothorax, n (%)	1 (1.1)	0 (0)	0.3	
Urinary leakage, n (%)	2 (2.1)	1 (1)	0.5	

TABLE 4 Intraoperative and postoperative complications in the overall population (n=195).

TABLE 5 Multivariate logistic regression analyses to predict the adoption of selective or super-selective clamping and the achievement of Trifecta in patients underwent PN (175), evaluating separately PADUA score (Model 1) and R.E.N.A.L. score (Model 2).

_	ADOPTION OF SELECTIVE OR SUPER-SELECTIVE CLAMPING			ACHIEVEMENT OF TRIFECTA				
	MODEL 1		MODEL 2		MODEL 1		MODEL 2	
	OR (95% CI)	P value	OR (95% CI)	P value	OR (95% CI)	P value	OR (95% CI)	P value
Age at surgery (years)	-	_	-	_	0.99 (0.95-1.02)	0.8	0.98 (0.95-1.02)	0.9
ASA score	-	-	-	-				
1-2					1.0 (Ref)	0.3	1.0 (Ref)	0.4
≥3					1.51 (0.64-3.72)		1.47 (0.62-3.50)	
PADUA score	1.19 (0.94-1.49)	0.1	-	-	0.86 (0.70-1.07)	0.2	-	-
RENAL score	-	-	1.07 (0.86-1.32)	0.6	-	-	0.86 (0.71-1.04)	0.1
3D virtual model								
No	1.0 (Ref)	< 0.001	1.0 (Ref)	< 0.001	1.0 (Ref)	0.01	1.0 (Ref)	0.02
Yes	5.26 (2.22-12.50)		5.04 (2.14-11.88)		2.42 (1.19-4.92)		2.41 (1.18-4.90)	
Surgical approach								
Open	1.0 (Ref)	0.2	1.0 (Ref)	0.2	1.0 (Ref)	0.7	1.0 (Ref)	0.4
Laparoscopic	0.33 (0.03-3.31)	0.3	0.28 (0.03-2.83)	0.3	0.59 (0.15-2.35)	0.5	0.59 (.015-2.32)	0.7
Robot assisted	1.68 (0.55-5.14)	0.4	1.60 (0.53-4.86)	0.4	0.85 (0.28-2.49)	0.8	0.83 (0.28-2.43)	0.1

OR, Odd Ratio; CI, Confidence Interval; ASA, American Society of Anesthesiologists.

protective effect of 3D models on postoperative renal function may be due to higher adoption of selective clamping (36.3%) in our cohort and higher adoption of clampless approach (50.9%) in the series by Michiels et al (22). Moreover, the potential benefit of higher adoption of clampless approach (36.9%) in control group on postoperative renal function may be mitigated by significant adoption of main artery clamping (53.6%). Of note, the preoperative planning using the 3D virtual model is more accurate and surgeons revealed higher adherence to the preoperative planning during surgery, with lower risk of unexpected events or to change the predetermined plan of surgery (Figure 4).

Third, the use of 3D models led to improve quality of PN since the overall Trifecta achievement was significantly higher in study group (80.2%) compared to control group (63.1%). Similarly to other experience (22), in our cohort, the use of 3D model is independent predictor of Trifecta achievement even adjusting for surgical technique (6). To note, these findings may be limited by selection bias due to lacking of randomizations between the two groups, since patients in study group had higher

Frontiers in Oncology



#### FIGURE 3

(A) Surgical planning of scheduled PN based on 2D imaging; (B) After revision of 3D model the planning of surgery was converted to RN before surgery, due to suspicious invasion of urinary collecting system and renal sinus.



#### FIGURE 4

(A) Selective clamping of primary arterial branching (arrows in axial/coronal views and in 3D rendering), resulting from preoperative planning based on standard 2D CT imaging; (B) Super-selective clamping of tertiary arterial branching (arrow), resulting from preoperative planning based on 3D model.

use of robotic approach, better comorbidities profile and lower tumour's volume compared to control group, despite no significant difference at baseline characteristics. Finally, the proportion of patients with  $\leq$ 30% postoperative eGFR reduction from baseline at discharge was significantly higher in Study group. Thus, the higher adoption of selective clamping provided by 3D models may reduce the level of nephron loss due to hypoxia (32), however, long terms data are needed to assess the real effect of 3D-guided PN on renal functional outcomes.

Despite several strengths, our study is not avoided from limitations. First, the lack of randomization between the two groups. Second, the inclusion of patients who underwent surgery with open, laparoscopic and robotic approach may affect surgical outcomes. Third, 3D model reconstruction is intrinsically affected by inaccuracies due to errors that may occur for poor CT scan resolution and/or inaccurate image segmentation process. Finally, limited follow up did not allow to assess conclusion concerning the real impact of 3D-guided PN on long term residual renal function compared to standard 2D approach.

Despite such limitations, the technologic progress would improve the precision of 3D reconstruction to simplify surgical planning and the intraoperative 3D navigation during PN. In the next future, 3D virtual models may represent an essential tool for multiple needs of NSS: patients' counseling, trainers' education, standardize the surgical complexity, improve the efficiency of surgical planning and the quality of patient-tailored surgery.

In conclusion, the use of 3D models may improve the efficiency of surgical planning, reducing the risk of conversion to RN during surgery. Moreover, a 3D-guided approach to PN increase the adoption of selective clamping and better predict the

achievement of Trifecta. Thus, the 3D virtual models applied to PN may improve the quality of surgery with potential implication on patient's outcomes.

## Data availability statement

The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.

#### **Ethics statement**

Approval of the research protocol by an Institutional Reviewer Board: IRB approval 3386/2018. The patients/ participants provided their written informed consent to participate in this study.

## Author contributions

LB, LC, FC, RS contributed to conception and design of the study. FC, GC, CG, AB, LT organized the database. BB, PP, MD, SB performed the statistical analysis. LB, BB, LC, EM, SL wrote the first draft of the manuscript. CG, GC, RG, EB, RS, LT, AB wrote sections of the manuscript. All authors contributed to manuscript revision, read, and approved the submitted version.

# Funding

The work reported in this publication was funded by the Italian Ministry of Health, **RC-2022-2773318.** 

## Acknowledgments

Authors acknowledge Fondazione CARISBO of Bologna (Italy).

# Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

## Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

## References

1. Kane CJ, Mallin K, Ritchey J, Cooperberg MR, Carroll PR. Renal cell cancer stage migration: analysis of the national cancer data base. *Cancer* (2008) 113(1):78–83. doi: 10.1002/cncr.23518

2. Schiavina R, Mari A, Antonelli A, Bertolo R, Bianchi G, Borghesi M, et al. A snapshot of nephron-sparing surgery in Italy: a prospective, multicenter report on clinical and perioperative outcomes (the RECORd 1 project). *Eur J Surg Oncol* (2015) 41(3):346–52. doi: 10.1016/j.ejso.2014.12.001

3. Schiavina R, Mari A, Bianchi L, Amparore D, Antonelli A, Artibani W, et al. Predicting positive surgical margins in partial nephrectomy: A prospective multicentre observational study (the RECORd 2 project). *Eur J Surg Oncol J Eur Soc Surg Oncol Br Assoc Surg Oncol* (2020) 46(7):1353–9. doi: 10.1016/ j.ejso.2020.01.022

 Ljungberg B, Albiges L, Abu-Ghanem Y, Bensalah K, Dabestani S, Fernandez-Pello S, et al. European Association of urology guidelines on renal cell carcinoma: The 2019 update. *Eur Urol* (2019) 75(5):799–810. doi: 10.1016/ j.eururo.2019.02.011

5. Borghesi M, Schiavina R, Gan M, Novara G, Mottrie A, Ficarra V. Expanding utilization of robotic partial nephrectomy for clinical T1b and complex T1a renal masses. *World J Urol* (2013) 31(3):499–504. doi: 10.1007/s00345-013-1095-2

6. Bianchi L, Schiavina R, Borghesi M, Chessa F, Casablanca C, Angiolini A, et al. Which patients with clinical localized renal mass would achieve the trifecta after partial nephrectomy? the impact of surgical technique. *Minerva Urol Nefrol* (2019) 72(3):339–49. doi: 10.23736/S0393-2249.19.03485-4

7. Mir MC, Derweesh I, Porpiglia F, Zargar H, Mottrie A. Autorino r. partial nephrectomy versus radical nephrectomy for clinical T1b and T2 renal tumors: A systematic review and meta-analysis of comparative studies. *Eur Urol* (2017) 71 (4):606–17. doi: 10.1016/j.eururo.2016.08.060

8. Bertolo R, Autorino R, Simone G, Derweesh I, Garisto JD, Minervini A, et al. Outcomes of robot-assisted partial nephrectomy for clinical T2 renal tumors: A

multicenter analysis (ROSULA collaborative group). Eur Urol (2018) 74(2):226–32. doi: 10.1016/j.eururo.2018.05.004

9. Galvin DJ, Savage CJ, Adamy A, Kaag M, O'Brien MF, Kallingal G, et al. Intraoperative conversion from partial to radical nephrectomy at a single institution from 2003 to 2008. *J Urol* (2011) 185(4):1204–9. doi: 10.1016/ j.juro.2010.11.077

10. Kara Ö, Maurice MJ, Mouracade P, Malkoç E, Dagenais J, Nelson RJ, et al. When partial nephrectomy is unsuccessful: Understanding the reasons for conversion from robotic partial to radical nephrectomy at a tertiary referral center. *J Urol* (2017) 198(1):30–5. doi: 10.1016/j.juro.2017.01.019

11. Bianchi L, Barbaresi U, Cercenelli L, Bortolani B, Gaudiano C, Chessa F, et al. The impact of 3D digital reconstruction on the surgical planning of partial nephrectomy: A case-control study. still time for a novel surgical trend? *Clin Genitourin Cancer* (2020) 18(6):e669–78. doi: 10.1016/j.clgc.2020.03.016

12. Schiavina R, Bianchi L, Borghesi M, Chessa F, Cercenelli L, Marcelli E, et al. Three-dimensional digital reconstruction of renal model to guide preoperative planning of robot-assisted partial nephrectomy. *Int J Urol* (2019) 26(9):931–2. doi: 10.1111/iju.14038

13. Porpiglia F, Amparore D, Checcucci E, Manfredi M, Stura I, Migliaretti G, et al. Three-dimensional virtual imaging of renal tumours: a new tool to improve the accuracy of nephrometry scores. *BJU Int* (2019) 124(6):945–54. doi: 10.1111/bju.14894

14. Bianchi L, Schiavina R, Bortolani B, Cercenelli L, Gaudiano C, Carpani G, et al. Interpreting nephrometry scores with three-dimensional virtual modelling for better planning of robotic partial nephrectomy and predicting complications. *Urol Oncol* (2021) 39(12):836.e1–9. doi: 10.1016/j.urolonc.2021.07.024

15. Bianchi L, Schiavina R, Bortolani B, Cercenelli L, Gaudiano C, Mottaran A, et al. Novel volumetric and morphological parameters derived from threedimensional virtual modeling to improve comprehension of tumor's anatomy in patients with renal cancer. Eur Urol Focus (2021) S2405-4569(21)00217. doi: 10.1016/j.euf.2021.08.002

16. Martini A, Falagario UG, Cumarasamy S, Jambor I, Wagaskar VG, Ratnani P, et al. The role of 3D models obtained from multiparametric prostate MRI in performing robotic prostatectomy. *J Endourol* (2022) 36(3):387–93. doi: 10.1089/ end.2021.0541

17. Falagario U, Veccia A, Weprin S, Albuquerque EV, Nahas WC, Carrieri G, et al. Robotic-assisted surgery for the treatment of urologic cancers: recent advances. *Expert Rev Med Devices* (2020) 17(6):579–90. doi: 10.1080/17434440.2020.1762487

18. Schiavina R, Bianchi L, Lodi S, Cercenelli L, Chessa F, Bortolani B, et al. Real-time augmented reality three-dimensional guided robotic radical prostatectomy: Preliminary experience and evaluation of the impact on surgical planning. *Eur Urol Focus* (2020) 7(6):1260–7. doi: 10.1016/j.euf.2020.08.004

19. Bianchi L, Chessa F, Angiolini A, Cercenelli L, Lodi S, Bortolani B, et al. The use of augmented reality to guide the intraoperative frozen section during robotassisted radical prostatectomy. *Eur Urol* (2021) 80(4):480–8. doi: 10.1016/ j.eururo.2021.06.020

20. Porpiglia F, Fiori C, Checcucci E, Amparore D, Bertolo R. Hyperaccuracy three-dimensional reconstruction is able to maximize the efficacy of selective clamping during robot-assisted partial nephrectomy for complex renal masses. *Eur Urol* (2018) 74(5):651–60. doi: 10.1016/j.eururo.2017.12.027

21. Schiavina R, Bianchi L, Chessa F, Barbaresi U, Cercenelli L, Lodi S, et al. Augmented reality to guide selective clamping and tumor dissection during robotassisted partial nephrectomy: A preliminary experience. *Clin Genitourin Cancer* (2020) 19(3):e149–55. doi: 10.1016/j.clgc.2020.09.005

22. Michiels C, Khene Z-E, Prudhomme T, Boulenger de Hauteclocque A, Cornelis FH, Percot M, et al. 3D-image guided robotic-assisted partial nephrectomy: a multi-institutional propensity score-matched analysis (UroCCR study 51). *World J Urol* (2021) 2. doi: 10.1007/s00345-021-03645-1

23. Hung AJ, Cai J, Simmons MN, Gill IS. "Trifecta" in partial nephrectomy. J Urol (2013) 189(1):36–42. doi: 10.1016/j.juro.2012.09.042

24. Borghesi M, Schiavina R, Chessa F, Bianchi L, La Manna G, Porreca A, et al. Retroperitoneal robot-assisted versus open partial nephrectomy for cT1 renal tumors: A matched-pair comparison of perioperative and early oncological outcomes. *Clin Genitourin Cancer* (2017) 16(2):e391-6. doi: 10.1016/j.clgc.2017.09.010

25. Schiavina R, Borghesi M, Chessa F, Rizzi S, Martorana G. [Predictors of positive surgical margins after nephron-sparing surgery for renal cell carcinoma: retrospective analysis on 298 consecutive patients]. *Urologia* (2014) 81(1):40–5. doi: 10.5301/uro.5000061

26. Novara G, La Falce S, Kungulli A, Gandaglia G, Ficarra V, Mottrie A. Robotassisted partial nephrectomy. *Int J Surg* (2016) 36(Pt C):554–9. doi: 10.1016/ j.ijsu.2016.05.073

27. Ficarra V, Novara G, Secco S, Macchi V, Porzionato A, De Caro R, et al. Preoperative aspects and dimensions used for an anatomical (PADUA) classification of renal tumours in patients who are candidates for nephron-sparing surgery. *Eur Urol* (2009) 56(5):786-93. doi: 10.1016/j.eururo.2009.07.040

28. Kutikov A, Uzzo RG. The R.E.N.A.L. nephrometry score: a comprehensive standardized system for quantitating renal tumor size, location and depth. *J Urol* (2009) 182(3):844–53. doi: 10.1016/j.juro.2009.05.035

29. Dindo D, Demartines N, Clavien P-A. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. *Ann Surg* (2004) 240(2):205–13. doi: 10.1097/01.sla.0000133083.54934.ae

30. Mitropoulos D, Artibani W, Graefen M, Remzi M, Rouprêt M, Truss M. Reporting and grading of complications after urologic surgical procedures: an ad hoc EAU guidelines panel assessment and recommendations. *Eur Urol* (2012) 61 (2):341–9. doi: 10.1016/j.eururo.2011.10.033

31. Anceschi U, Ferriero MC, Tuderti G, Brassetti A, Bertolo R, Capitanio U, et al. Head to head impact of margin, ischemia, complications, score versus a novel trifecta score on oncologic and functional outcomes after robotic-assisted partial nephrectomy: Results of a multicenter series. *Eur Urol Focus* (2021) 7(6):1391–9. doi: 10.1016/j.euf.2020.06.021

32. Simone G, Gill IS, Mottrie A, Kutikov A, Patard J-J, Alcaraz A, et al. Indications, techniques, outcomes, and limitations for minimally ischemic and offclamp partial nephrectomy: a systematic review of the literature. *Eur Urol* (2015) 68 (4):632–40. doi: 10.1016/j.eururo.2015.04.020

33. Khandwala YS, Jeong IG, Kim JH, Han DH, Li S, Wang Y, et al. The incidence of unsuccessful partial nephrectomy within the united states: A nationwide population-based analysis from 2003 to 2015. *Urol Oncol* (2017) 35 (12):672.e7–672.e13:. doi: 10.1016/j.urolonc.2017.08.014

34. Rais-Bahrami S, Lima GC, Varkarakis IM, Romero FR, Trock B, Jarrett TW, et al. Intraoperative conversion of laparoscopic partial nephrectomy. *J Endourol* (2006) 20(3):205–8. doi: 10.1089/end.2006.20.205